X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The in vitro data, in GBM cells and patient-derived glioma-initiating cells, show anti-tumour activity of the Company's lead asset SFX-01. In both models, SFX-01 reduced tumour growth substantially and demonstrated statistically significant improved survival.
Lead Product(s): Sulforaphane
Therapeutic Area: Oncology Product Name: SFX-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2021
Details:
The net proceeds of the Fundraising are intended to be used to complete the formulation and scale up manufacturing of SFX-01 and other R&D nd general corporate purposes.
Lead Product(s): Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area: Oncology Product Name: SFX-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $15.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 02, 2021
Details:
The data generated for SFX-01 in standard pre-clinical models and orthotopic models (where glioma cells are implanted in brain tissue representing a more disease-relevant model) show tumour shrinkage and significantly extended survival times.
Lead Product(s): Sulforaphane
Therapeutic Area: Oncology Product Name: SFX-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
A total of 56 patients had been recruited and randomised to the STAR trial ("SFX-01 treatment for Acute Respiratory Infections").SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress.
Lead Product(s): Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area: Infections and Infectious Diseases Product Name: SFX-01
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Dundee
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2021
Details:
This Phase II/III trial will investigate whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with community-acquired pneumonia who have been or are being tested for suspected COVID-19.
Lead Product(s): Sulforaphane
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: SFX-01
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
Under the agreement, Evgen will supply SFX-01 to support a potential future clinical trial led by University of Rochester Nephrology division chief Thu Le.
Lead Product(s): SFX-01
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: University of Rochester School of Medicine & Dentistry
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
